A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
| 대상 질환 | Non-Small Cell Lung Cancer |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | AstraZeneca |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 30 명 |
| 중재(약물) | Osimertinib + Savolitinib, Savolitinib + Placebo |
| 시작일 | 2020년 9월 28일 |
| 완료일 | 2022년 12월 21일 |
| 결과 공개일 | 2024년 9월 24일 |
요약
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Objective Response Rate (ORR)
| Savolitinib Plus Osimertinib | 57.1 Percentage of participants |
|---|---|
| Savolitinib Plus Placebo | 12.5 Percentage of participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC